Drug Trial Radar · NCT04487080
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,074
Actual
Start
Sep 30, 2020
Primary completion
Aug 11, 2023
Study completion Feb 16, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
AmivantamabDrug
Participants will receive amivantamab intravenously.
OsimertinibDrug
Participants will receive osimertinib capsules orally.
LazertinibDrug
Participants will receive lazertinib tablets orally.
PlaceboDrug
Participants will receive matching placebo orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: From randomization to either disease progression or death whichever occurs first (up to 32.8 months)
Locations
269 sites in 28 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC - HAL
Goodyear, Arizona
Yuma Regional Medical Center
Yuma, Arizona
City of Hope Long Beach Elm
Long Beach, California
University of California Irvine
Orange, California
Rocky Mountain Cancer Centers
Lone Tree, Colorado
Cancer Specialists of North Florida
Jacksonville, Florida
University Cancer And Blood Center LLC
Athens, Georgia
East Jefferson General Hospital
Metairie, Louisiana
Maryland Oncology Hematology, PA
Columbia, Maryland
Henry Ford Hospital
Detroit, Michigan
Minnesota Oncology Hematology P A
Edina, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University School Of Medicine
St Louis, Missouri
Astera Cancer Care
East Brunswick, New Jersey
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology P A
Austin, Texas
Oncology Consultants Texas
Houston, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Centro Oncológico Korben
Buenos Aires, Argentina
Instituto Alexander Fleming
Buenos Aires, Argentina
Hospital Privado Centro Medico de Cordoba
Córdoba, Argentina
Centro Oncologico Riojano Integral (Cori)
La Rioja, Argentina
Clínica Viedma
Viedma, Argentina
Flinders Medical Centre
Bedford Park, Australia
Austin Hospital
Heidelberg, Australia
Cabrini Medical Centre
Malvern, Australia
St John of God Hospital Murdoch
Murdoch, Australia
Sir Charles Gairdner Hospital
Nedlands, Australia
Westmead Hospital
Westmead, Australia
Southern Medical Day Care Centre
Wollongong, Australia
Princess Alexandra Hospital
Woolloongabba, Australia
Cliniques Universitaires Saint Luc
Brussels, Belgium
Grand Hopital De Charleroi Site Les Viviers
Charleroi, Belgium
UZ Leuven
Leuven, Belgium
Clinique Saint Pierre
Ottignies, Belgium
Algemeen Ziekenhuis Delta
Roeselare, Belgium
Fundacao Pio XII
Barretos, Brazil
Cetus Oncologia
Belo Horizonte, Brazil
Showing 40 of 269 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.